It took months to analyze Covid-19, develop vaccine candidates, test them, produce them, and start distributing them to the masses. Steps were skipped or curtailed, of course, as Big Pharma companies raced to cash in on billions of dollars worth of jabs.
As Pfizer executive Janine Small said to the EU Parliament last month, they were “moving at the speed of science.”
But after the huge rush to put out products exemplified corporate fiscal “science” at its worst in 2020, the last two years have seen real science grind to a halt. Producing the jabs happened in record time but analyzing the adverse reactions, reporting on studies, revealing the true lack of efficacy, and investigating deaths are moving slower than molasses. This is by design.
The perfect example of this is the sad story of Joseph McGinty, a 14-year-old boy who died three weeks after getting his jabs. It has been nearly 15-months since he died and they’re just now getting around to launching an investigation into what killed him. What’s worse is they’re saying the investigation may take years before they have results. If the jabs are as dangerous as many of us believe (hint: they are), the verdict from this medical investigation will only come out after it’s way too late for the masses.
Below is my commentary on the matter, followed by an article by Suzanne Burdick, Ph.D., from The Defender.
Teen’s Death 3 Weeks After Pfizer Vaccine Triggers Investigation
The death last year of a 14-year-old Irish teen three weeks after he received Pfizer’s COVID-19 vaccine has sparked a “considerable investigation” that will include requests to Pfizer for safety information, officials involved in an inquest into the teen’s death said this week.
The death last year of a 14-year-old Irish teen three weeks after he received Pfizer’s COVID-19 vaccine has sparked an investigation that could take years, officials involved in an inquest into the teen’s death said this week.
As part of the “considerable investigation,” authorities said they will request safety information about the vaccine from Pfizer.
Joseph McGinty, a secondary school student from Achill Island, Ireland, received the Pfizer vaccine on Aug. 20, 2021. On Sept. 1, 2021, he was hospitalized overnight at Mayo University Hospital and discharged the following day.
On Sept. 8, 2021, McGinty revisited the hospital for review. He died at home on Sept. 13, 2021.
Patricia McGinty formally identified her son’s remains on the day of his death but “has very little recollection of the morning in question,” the family’s attorney, Rita Kilroy, told the court.
The coroner involved in the case, Pat O’Connor, called McGinty’s death “a matter of significant public concern.”
“The circumstances of Joseph McGinty’s death is that COVID vaccination was administered to him [and] that there appears to have been either a reaction or a significant change in his medical circumstances following the administration of the vaccine and that subsequently, unfortunately, Master McGinty died,” O’Connor said in Monday’s hearing.
Kilroy told the court this week, “We would perceive there to be a concern for public health and safety and potential for recurrence in two circumstances.”
An inquest is a formal investigation conducted by a coroner in order to determine how someone died. The purpose of an inquest is limited to establishing the identity of the deceased individual as well as where, when and how they died.
At the request of Kilroy, O’Connor agreed to make a request for legal aid and legal advice for the McGinty family under Section 60 of the Coroners Act, 1962.
The inquest into McGinty’s death will resume on Dec. 20.
Studies link COVID-19 vaccines, including Pfizer’s, to negative health outcomes — especially among young men — including death.
In June 2021, The Defender reported on the death of 13-year-old Jacob Clynick just three days after he received the second dose of Pfizer’s COVID-19 vaccine.
The Centers for Disease Control and Prevention declined to investigate Clynick’s death, even though the death was reported to the agency’s Vaccine Adverse Event Reporting System (VAERS).
Between Dec. 14, 2020, and Nov. 11, 2022, there have been nine deaths reported to VAERS following COVID-19 vaccines among children ages 6 months to 5 years, 31 deaths reported among children 5 to 12 years old and 133 deaths among teens 12 to 18 years old.
Last month, Florida Surgeon General Joseph Ladapo, M.D., Ph.D., recommended against mRNA COVID-19 vaccination of males ages 18 to 39 years given the results of a study that found an 84% increase in the risk of cardiac death among young adult males within 28 days of mRNA COVID-19 vaccination.
Since March, Florida has recommended against mRNA COVID-19 vaccination of healthy children and adolescents younger than 18.
On Sept. 30, Sweden announced it would no longer recommend COVID-19 vaccination for children ages 12 to 17 and in Denmark, COVID-19 vaccines are not recommended for anyone under 50 years old.
This article was originally published by The Defender — Children’s Health Defense’s News & Views Website under Creative Commons license CC BY-NC-ND 4.0. Please consider subscribing to The Defender or donating to Children’s Health Defense.
Bypass Big Tech Censors
Why Bullion Beats Numismatics and Collectible for Your Safe or IRA
Precious metals continue to attract Americans seeking reliable ways to protect their wealth amid inflation, geopolitical risks, and stock market swings. Whether stored in a home safe or held inside a self-directed IRA, physical gold and silver deliver tangible value that paper or digital assets often lack. Yet investors must choose carefully between bullion—pure bars and coins valued mainly for their metal content—and numismatics or collectibles, where rarity, history, and collector demand heavily influence pricing.
Advisor Bullion serves as a dependable source for straightforward, high-quality bullion. The company specializes in physical gold, silver, platinum, and palladium, emphasizing transparent pricing and products that deliver maximum metal content for every dollar spent. This approach makes it ideal for both personal holdings and retirement accounts.
Bullion consists of refined precious metals in standard forms like one-ounce coins (American Gold Eagles, Silver Eagles, Canadian Maple Leafs) or bars. Their value tracks closely to the current spot price of the metal. A typical gold bullion coin trades near the live gold spot price plus a small premium. This structure keeps costs clear and predictable.
Numismatic coins and collectibles add substantial value from factors such as age, rarity, minting errors, or historical significance. A pre-1933 U.S. gold coin or graded proof piece can carry premiums of 30%, 50%, or even 200% above melt value. While this appeals to hobbyists, it creates complexity. Pricing depends on subjective grading, collector trends, and auction results instead of daily spot prices.
For investors focused on wealth preservation and retirement security rather than building a collection, bullion often delivers better results.
Lower Costs and Better Liquidity for Home Storage
When keeping metals in a home safe or private vault, liquidity and efficiency count. Bullion offers clear benefits:
- You acquire more actual gold or silver per dollar invested. Numismatics divert a large share of your money into rarity premiums and massive sales commission, reducing your metal exposure.
- Selling bullion involves tight bid-ask spreads, so you recover nearly full spot value with minimal fees. Collectibles require finding the right buyer and may sell at a discount if demand for that specific item weakens.
- Bullion prices remain transparent and update with global spot markets. You can track gold near current levels or silver accordingly and know exactly where your holdings stand. Numismatic values are priced by the Gold IRA companies with hefty margins applied.
- Standardized coins and bars store efficiently and divide easily for partial sales. Rare coins often need protective slabs and controlled conditions, adding hassle and expense.
- Bullion enjoys worldwide acceptance. A 1-oz Gold Maple Leaf or Silver Eagle sells quickly to dealers anywhere. Niche numismatic pieces may appeal only to limited buyers, slowing liquidation when speed matters.
In times when quick access to value becomes important, bullion’s simplicity stands out.
Stronger Fit for Precious Metals IRAs
Precious metals IRAs continue gaining traction as investors diversify retirement portfolios beyond stocks and bonds. IRS rules permit certain bullion products in self-directed IRAs if they meet purity standards (.995 fine for gold, .999 for silver) and are held by an approved custodian. Eligible items include American Gold and Silver Eagles plus many generic bars and rounds from recognized mints.
Numismatic and most collectible coins generally face heavy scrutiny from custodians due to valuation disputes and elevated markups. These higher premiums mean less actual metal ends up working inside the account.
Bullion avoids these issues. Its value links directly to verifiable spot prices, which simplifies reporting and lowers the risk of regulatory challenges. More of your IRA contribution purchases real metal instead of dealer profits or speculative upside. Over time, owning additional ounces that appreciate with the metal itself can create meaningful outperformance compared with high-premium alternatives that deliver fewer ounces.
Regulatory guidance from the CFTC and state securities offices repeatedly cautions against aggressive sales of expensive numismatics or “semi-numismatic” coins for IRAs. For retirement planning, transparent bullion from established providers reduces risk and aligns better with long-term goals.
How to Get Started with Bullion
Begin by clarifying your goals. Are you protecting savings in a safe, or moving part of a retirement account into a precious metals IRA? Focus on the number of ounces you can acquire at current prices rather than chasing marked-up collectibles.
Diversify sensibly: use gold for core preservation and silver for its blend of industrial and monetary qualities. Mix coins for easier divisibility with bars for lower per-ounce costs on larger buys. Arrange secure storage—whether at home with proper insurance or through professional facilities.
As economic uncertainties linger and faith in conventional assets erodes, bullion continues proving its worth as a dependable store of value. Its direct approach avoids the hype that sometimes surrounds collectible markets and keeps the focus on the metal itself.
For investors prepared to strengthen their portfolios, Advisor Bullion supplies the expertise and selection needed to acquire high-quality bullion efficiently. Whether building personal holdings or integrating metals into an IRA, their emphasis on transparent, investment-grade products helps secure more ounces today that support greater financial security tomorrow. In a complicated financial landscape, bullion’s clarity and reliability make it the smarter foundation for protecting what matters most.
